An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults

Current Medical Research and Opinion

Volumn 23, Issue 2, 2007, Pages 293-299

  Richards, J B ^a   Cherkas, L F ^a   Spector, T D ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Compliance; Dosing regimens; Osteoporosis; Osteoporotic fractures

Indexed keywords

ALENDRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; QUESTIONNAIRE; TREATMENT RESPONSE;

AGED; COHORT STUDIES; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTURE; QUESTIONNAIRES; RALOXIFENE; REGISTRIES; SINGLE-BLIND METHOD; TERIPARATIDE; THIOPHENES; TWINS;

EID: 33847356144     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X162764     Document Type: Article

References (21)

1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull WHO 2003;81:646-56
2. World Health Organization. Consensus development conference: prophylaxis and treatment of osteoporosis. Osteoporos Int 1991;1:114-7
3. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
4. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - a randomized controlled trial. JAMA 1999;282:1344-52
5. Ettinger B. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45. Erratum in: JAMA 1999;282:2124
6. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005;90:2816-22
7. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
8. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-9
9. Yood R, Emani S, Reed J, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-8
10. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8
11. Hideaki K, Masao F, Kazuhiro K, et al. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5 mg once-daily dosage regimen. J Bone Min Metab 2006;24:405-13
12. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calc Tiss Int 2002;71:103-11
13. Nelson BW, Robert L, Zhengqing L, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003;14:437-41
14. Greenspan SL, Bone G, Schnitzer TJ, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Min Res 2002;17:1988-96
15. Andrew T, Hart DJ, Snieder H, et al. Are twins and singletons comparable? A study of disease-related and lifestyle characteristics in adult women. Twin Res 2001;4:464-77
16. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21
17. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clinic Proceedings 2005;80:856-61
18. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259-62
19. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Man Care Pharm 1998;4:488-92
20. Weiss TW, Gold DT, Silverman SL, et al. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin 2006;22:949-60
21. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-6